Effects of different levels of endotoxin contamination on inflammatory cytokine production by peripheral blood mononuclear cells after high-flux hemodialysis

Blood Purification

Volumn 32, Issue 2, 2011, Pages 112-116

  Praditpornsilpa, Kearkiat ^a   Tiranathanagul, Khajohn ^a   Susantitaphong, Paweena ^a   Katavetin, Pisut ^a   Trakarnvanich, Thananda ^b   Townamchai, Natavudh ^a   Kanjanabuch, Talerngsak ^a   Avihingsanon, Yingyos ^a   Tungsanga, Kriang ^a   Eiam Ong, Somchai ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

Author keywords

Cytokine; Dialysate; Endotoxin

Indexed keywords

ENDOTOXIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; ARTICLE; BACTERIUM CONTAMINATION; BLOOD FLOW VELOCITY; CELL ISOLATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENSITY GRADIENT CENTRIFUGATION; DIABETIC NEPHROPATHY; DIALYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY POLYCYSTIC DISEASE; MALE; OBSTRUCTIVE UROPATHY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT; THERAPY EFFECT;

ADULT; AGED; ENDOTOXINS; EQUIPMENT CONTAMINATION; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RENAL DIALYSIS; THAILAND;

EID: 79953031324     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000324394     Document Type: Article

References (20)

1. Baurmeister U, Travers M, Vienken J, Harding G, Million C, Klein E, Pass T, Wright R: Dialysate contamination and back filtration may limit the use of high-flux dialysis membranes. ASAIO Trans 1989; 35: 519-522. (Pubitemid 20118289)
2. Bommer J, Becker KP, Urbaschek R: Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol 1996; 7: 883-888. (Pubitemid 27465982)
3. Weber V, Linsberger I, Rossmanith E, Weber C, Flakenhagen D: Pyrogen transfer across high-and low-flux hemodialysis membrane. Artif Organs 2004; 28: 210-217. (Pubitemid 38339004)
4. Raij L, Shapiro FL, Micheal AF: Endotoxemia in febrile reactions during hemodialysis. Kidney Int 1973; 4: 57-60.
5. Stenvinkel P: Inflammation in end-stage renal disease -a fire that burns within. Contrib Nephrol 2005; 149: 185-199. (Pubitemid 43265016)
6. Lonnemann G: Chronic inflammation in hemodialysis: The role of contaminated dialysate. Blood Purif 2000; 18: 214-223. (Pubitemid 30619960)
7. Nakatani T, Tsuchida K, Sugimura K, Yoshimura R, Takemoto Y: Response of peripheral blood mononuclear cells in hemodialysis patients against endotoxin and muramyldipeptide. Int J Mol Med 2002; 10: 469-472.
8. Arizono K, Nomura K, Motoyama T, Matsushita Y, Matsuoka K, Miyazu R, Takeshita H, Fukui H: Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22(suppl 2):26-29.
9. Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Ashikaga E, Matsumoto K, Mukai M, Watanabe M, Akizawa T: Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif 2009; 28: 29-39.
10. AAMI Standards and Recommended Practices, ANS/AAMI RD62: 2006 Water Treatment Equipment for Hemodialysis Applications. Arlington, Association for the Advance of Medical Instrumentation, 2007.
11. Section IV: Dialysis fluid purity. European Best Practice Guidelines for Hemodialysis (part 1). European Dialysis and Transplantation Association. Nephrol Dial Transplant 2002; 17(suppl 7):45-62.
12. International Organization for Standardization: Quality of dialysis fluid for haemodialysis and related therapies. Geneva, ISO, 2009.
13. Kawanishi H, Akiba T, Masakane I, Tomo T, Mineshima M, Kawasaki T, Hirakata H, Akizawa T: Standard on microbiological management of fluids for hemodialysis and related therapies by the Japanese Society for Dialysis Therapy 2008. Ther Apher Dial 2009; 13: 161-166.
14. Pereira BJG, Snodgrass B, Barber G, Perella C, Chopra S, King AJ: Cytokines production during in vitro hemodialysis with new and formaldehyde-or renalin-reprocessed cellulose dialyzers. J Am Soc Nephrol 1995; 6: 1304-1308.
15. Ledebo I: Ultrapure dialysate fluid-how pure is it and do we need it? Nephrol Dial Transplant 2007; 22: 20-23. (Pubitemid 46050319)
16. Hsu PY, Lin CL, Yu CC, Chien CC, Hsiau TG, Sun TH, Huang LM, Yang CW: Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients -a prospective cross-over study. J Nephrol 2004; 17: 693-700.
17. Matsuhashi N, Yoshioka T: Endotoxin-free dialysis improves response to erythropoietin in hemodialysis patients. Nephron 2002; 92: 601-604.
18. Masakane I: Review: Clinical usefulness of ultrapure dialysate -recent evidence and perspectives. Ther Apher Dial 2006; 10: 348-354. (Pubitemid 44154765)
19. Bommer J, Jaber BL: Ultrapure dialysate: Facts and myths. Semin Dial 2006; 19: 115-119. (Pubitemid 43468643)
20. Pisitkun T, Eiam-Ong S, Tiranathanagul K, Sakunsrijinda C, Manotham K, Hanvivatvong O, Suntaranuson P, Praditpornsilpa K, Chusil S, Tungsanga K: Convective-controlled double high flux hemodiafiltration: A novel blood purification modality. Int J Artif Organs 2004; 27: 195-204. (Pubitemid 38594353)